Company news

Praxis Precision Medicines, Inc. news in 2023

Praxis Precision Medicines, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

November 27, 2023

Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference

November 20, 2023

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

November 15, 2023

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 6, 2023

Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium

November 1, 2023

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

October 1, 2023

Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023

September 26, 2023

Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference

September 6, 2023

Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress

August 30, 2023

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress

August 27, 2023

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results

August 8, 2023

Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide

August 7, 2023

Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study

August 6, 2023

Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference

August 2, 2023

Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities

June 21, 2023

Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering

June 14, 2023

Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA

June 8, 2023

Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference

June 1, 2023

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 10, 2023

Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile

May 10, 2023

Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting

April 18, 2023

Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events

April 16, 2023

Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference

April 5, 2023

Praxis Precision Medicines to Present at Upcoming Investor Conferences

March 2, 2023

Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3

March 2, 2023

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

February 6, 2023

Decks in 2023